Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Takeda Pharmaceutical Co. Ltd (TAK)

Takeda Pharmaceutical Co. Ltd (TAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
4 Biotech Stocks That Could Keep Beating Wall Street

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

BMY : 58.15 (+0.22%)
LLY : 112.80 (-0.64%)
ACAD : 45.24 (+6.17%)
CHRS : 18.80 (-1.36%)
CELG : 109.57 (+0.03%)
BIIB : 294.14 (+0.30%)
INCY : 84.86 (-0.28%)
ADPT : 28.32 (+2.65%)
ALEC : 16.68 (-2.51%)
NGM : 12.82 (+1.26%)
TAK : 19.73 (-1.69%)
Takeda Reports Solid Second Quarter FY2019 Results and Raises Profit Guidance for the Full Year

Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):

TKPYY : 16.5900 (-0.90%)
TAK : 19.73 (-1.69%)
Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark

Seattle Genetics (SGEN) incurs wider-than-expected loss in third-quarter 2019 but rides high on revenue beat.

RHHBY : 37.5550 (+0.44%)
MRK : 83.28 (-0.37%)
SGEN : 108.30 (-0.04%)
TAK : 19.73 (-1.69%)
Easy Investing Secrets to an Early Retirement - October 11, 2019

Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments,...

TAK : 19.73 (-1.69%)
UGI : 46.23 (-0.67%)
T : 39.37 (-0.03%)
Signs That Your Trading Will Ruin Your Retirement - October 09, 2019

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

GLPI : 42.53 (+1.21%)
FMNB : 15.57 (unch)
TAK : 19.73 (-1.69%)
Karyopharm Signs $150M Royalty Agreement to Support Xpovio

Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.

JNJ : 131.98 (-0.77%)
CELG : 109.57 (+0.03%)
KPTI : 15.28 (+3.80%)
TAK : 19.73 (-1.69%)
Is Takeda (TAK) a Profitable Stock for Value Investors Now?

Let's see if Takeda (TAK) stock is a good choice for value-oriented investors right now from multiple angles.

TAK : 19.73 (-1.69%)
Takeda Reports Strong First Quarter FY2019 Results and Raises Guidance for the Full Year

Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK):

TKPYY : 16.5900 (-0.90%)
TAK : 19.73 (-1.69%)
How Do Earnings Impact The Stock Market?

Q2 Earnings Season is in full swing and Sheraz Mian joins the show to discuss everything you need to know!

DIS : 136.74 (-0.88%)
AMZN : 1,771.65 (-0.80%)
GOOGL : 1,298.28 (-0.82%)
SQ : 63.79 (+2.15%)
UAA : 17.57 (+0.06%)
TAK : 19.73 (-1.69%)
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates

Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.

MRK : 83.28 (-0.37%)
RHHBY : 37.5550 (+0.44%)
SGEN : 108.30 (-0.04%)
TAK : 19.73 (-1.69%)
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 19.73 (-1.69%)
J&J Submits BLA for Subcutaneous Formulation of Darzalex

Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.

JNJ : 131.98 (-0.77%)
RHHBY : 37.5550 (+0.44%)
CELG : 109.57 (+0.03%)
TAK : 19.73 (-1.69%)
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 19.73 (-1.69%)
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 19.73 (-1.69%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK

Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby...

TKPYY : 16.5900 (-0.90%)
TAK : 19.73 (-1.69%)
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status

The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.

JNJ : 131.98 (-0.77%)
RARE : 37.50 (-3.60%)
ARCT : 9.74 (-0.92%)
TAK : 19.73 (-1.69%)
J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma

Johnson & Johnson's (JNJ) label expansion application, seeking approval for Darzalex+Revlimid to treat transplant ineligible newly diagnosed patients with multiple myeloma, receives FDA approval.

RHHBY : 37.5550 (+0.44%)
JNJ : 131.98 (-0.77%)
CELG : 109.57 (+0.03%)
TAK : 19.73 (-1.69%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Takeda Pharmaceutical Company Limited - TAK

Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK). Such investors are advised to contact Robert S. Willoughby...

TKPYY : 16.5900 (-0.90%)
TAK : 19.73 (-1.69%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 19.73 (-1.69%)
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Takeda Pharmaceutical Company Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company")...

SHPG : 179.20 (+4.10%)
TKPYY : 16.5900 (-0.90%)
TAK : 19.73 (-1.69%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.30 , AIZ -0.99 , SBAC +0.16 , SO -0.79 , WELL +0.23
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar